Subscribe to RSS
DOI: 10.1055/s-2006-942388
Interesting Results of Catalytic Hydrogenation of 3-(2-Nitrophenyl)isoxazoles and 3-(Nitrophenyl)-4,5-dihydroisoxazoles [1]
Publication History
Publication Date:
08 May 2006 (online)

Abstract
The palladium-on-carbon assisted hydrogenolysis of substituted 3-(2-nitrophenyl)isoxazoles, irrespective of substitution on the isoxazole ring, invariably leads to reduction of the nitro to the amino group with concomitant regiospecific ring closure to yield substituted 4-aminoquinolines. In contrast similar hydrogenation of 3-(2-, 3-, and 4-nitrophenyl)-4,5-dihydroisoxazoles (2-isoxazolines) results in reduction of the nitro group only with conservation of the dihydroisoxazole ring to yield the corresponding 3-(aminophenyl)-4,5-dihydroisoxazoles.
Key words
isoxazole - 4-aminoquinoline - hydrogenation - ring transformation - regiospecific
CDRI Communication no 8402. A part of this work was presented as a poster at the CSIR-ACS conference OCCB-2006 at NCL Pune from 7-9th January, 2006.
-
2a
Godard A.Queguiner G. J. Heterocycl. Chem. 1980, 17: 465 -
2b
Veronese AC.Callegari SA.Salah SAA. Tetrahedron Lett. 1990, 31: 3485 - 3
Thomsen I.Torssel KBG. Acta Chem. Scand. B 1988, 42: 309 - 4
Jensen S.Torssel KBG. Acta Chem. Scand. B 1995, 19: 53 -
5a
Reuben BG.Wittcoff HA. Pharmaceutical Chemicals in Perspective Wiley; New York: 1989. -
5b
McIntosh HM.Greenwood BM. Ann. Trop. Med. Parasitol. 1998, 92: 265 -
5c
Deshpande SS.Sheridan RE.Adler M. Toxicon 1997, 35: 433 -
5d
Slater AF. Pharmacol. Ther. 1993, 57: 203 -
5e
O’Neill PM.Willock DJ.Hawley SR.Bray PG.Storr RC.Ward SA.Park BK. J. Med. Chem. 1997, 40: 437 ; and references therein -
5f
Madrid PB.Sherrill J.Liou AP.Weisman JL.DeRisi JL.Guy RK. Bioorg. Med. Chem. Lett. 2005, 15: 1015 -
6a
Andrews IP.Bannister R.Etridge SK.Lewis NJ.Mullane MV.Wells AS. Tetrahedron Lett. 1995, 36: 7743 -
6b
Ife RF.Brown TH.Keeling DJ.Leach CA.Meeson ML.Persons ME.Reavill DR.Theobald CJ.Wiggall KJ. J. Med. Chem. 1992, 35: 3413 - 7
Moyer MP.Weber FH.Gross JL.Isaac JW.Saint Fort R. Bioorg. Med. Chem. Lett. 1992, 2: 1589 - 8
Kireev DB.Chretien JR.Raevsky DA. Eur. J. Med. Chem. 1995, 30: 395 -
9a
Marco JL.Carreiras MC. Mini Rev. Med. Chem. 2003, 3: 518 -
9b
Doucet-Personeni C.Bentley PD.Fletcher RJ.Kinkaid A.Kryger G.Pirard B.Taylor A.Taylor R.Taylor J.Viner R.Silman I.Sussman JL.Greenblatt HM.Lewis T. J. Med. Chem. 2001, 44: 3203 -
9c
Han YF.Li CP.Chow E.Wang H.Pang YP.Carlier PR. Bioorg. Med. Chem. 1999, 7: 2569 - 10
Shinkai H.Ito T.Iida T.Kitao Y.Yamada H.Uchida I. J. Med. Chem. 2000, 43: 4667 - 11
Medebielle M.Hohn S.Okada E.Myoken H.Shibata D. Tetrahedron Lett. 2005, 46: 7817 - 12
Roy AK.Batra S. Synthesis 2003, 1347 - 13
Balsamo A.Coletta I.Guglielmotti A.Landolfi C.Mancini F.Martinelli A.Milanese C.Minutolo F.Nencetti S.Orlandini E.Pinza M.Rapposelli S.Rosello A. Eur. J. Med. Chem. 2003, 38: 157 -
14a
Saxena R.Singh V.Batra S. Tetrahedron 2004, 60: 10311 -
14b
Singh V.Saxena R.Batra S. J. Org. Chem. 2005, 70: 353 -
14c
Roy AK.Pathak R.Yadav GP.Maulik PR.Batra S. Synthesis 2006, in press - 15
Purwono B.Smalley RK.Porter TC. Synlett 1992, 231 -
16a
Kozikowski AP.Stein PD. J. Am. Chem. Soc. 1982, 104: 4023 -
16b
Curran DP. J. Am. Chem. Soc. 1982, 104: 4024 -
16c
Curran DP. J. Am. Chem. Soc. 1983, 105: 4024 -
16d
Auricchio S.Ricca A. Tetrahedron 1987, 43: 3983 - 17
Quan ML.Ellis CD.He MY.Liauw AY.Lam PYS.Rossi KA.Knabb RM.Luettgen JM.Wright MR.Wong PC.Wexler RR. Bioorg. Med. Chem. Lett. 2003, 13: 1023 - 18
Vittorio F.Ronsisvalle G.Pappalardo MS.Blandino G. Farmaco 1985, 40: 359 -
20a
Patra A.Batra S.Kundu B.Joshi BS.Roy R.Bhaduri AP. Synthesis 2001, 276 -
20b
Batra S.Roy AK.Patra A.Bhaduri AP.Surin WS.Raghvan SAV.Sharma P.Kapoor K.Dikshit M. Bioorg. Med. Chem. 2004, 12: 2059 - 21
Srivastava S.Bajpai LK.Batra S.Bhaduri AP.Maikuri JP.Gupta G.Dhar JD. Bioorg. Med. Chem. 1999, 7: 2607
References
CDRI Communication no 8402. A part of this work was presented as a poster at the CSIR-ACS conference OCCB-2006 at NCL Pune from 7-9th January, 2006.
19Crystal data of compound 7d: C10H9N3O, M = 187.2; orthorhombic, P212121, a = 5.710 (1), b = 9.925 (1), c = 16.153 (3) Å, V = 915.4 (3) Å3, Z = 4, D c = 1.358g cm-3, µ (Mo-Kα) = 0.09 mm-1, F(000) = 392.0, colorless block, crystal dimensions 0.225 × 0.175 × 0.150 mm, 1370 reflections measured (R int = 0.019), 1230 unique, R = 0.0456 [(Δ/σ)max = 000)], wR 2 = 0.1087 for 1270 on F 2 values of reflections with I>2σ(I), S = 1.028 for all data and 128 parameters. Unit cell determination and intensity data collection (2θ = 50°) were performed on a Bruker P4 diffractometer at 293 (2) K. Structure solutions was performed by direct methods and refinements by full-matrix least-squares methods on F 2. Programs: XSCANS [Siemens Analytical X-ray Instrument Inc.: Madison, WI, USA, 1996) was used for data collection and data processing], SHELXTL-NT [(Bruker Axs Inc.: Madison, Wisconsin, USA 1997) was used for structure determination, refinements and molecular graphics]. Further details of the crystal structure investigation can be obtained from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, UK (CCDC deposition no. of compound 7d: 297540.